GBP1 as a Machine Learning-Prioritized Biomarker and Therapeutic Target for Epstein-Barr Virus-Induced Clear Cell Renal Cell Carcinoma: Multi-Omics Causal Validation
December 2025
in “
International Journal of Surgery
”
TLDR GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.
This study investigates the role of Epstein-Barr virus (EBV) in clear cell renal cell carcinoma (ccRCC) and identifies GBP1 as a key biomarker and therapeutic target. Using Mendelian randomization and single-cell RNA sequencing, the researchers found that regulatory T cells and B cells mediate the risk of ccRCC driven by EBV-specific antibodies. Machine learning prioritized GBP1 among seven key genes, with SHAP and multi-omics validation confirming its significance. Drug prediction and molecular docking suggest that finasteride could inhibit GBP1, providing a potential new strategy for ccRCC prevention and treatment.